CytRx Announces Pricing of Public Offering of 10.0 Million Shares of Common Stock

  CytRx Announces Pricing of Public Offering of 10.0 Million Shares of Common
  Stock

Business Wire

LOS ANGELES -- October 8, 2013

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development
company specializing in oncology, today announced the pricing of its
previously announced underwritten public offering. CytRx is offering 10.0
million shares of common stock at a public offering price of $2.25 per share
for gross proceeds of $22.5 million, prior to deducting the underwriting
discount and estimated offering expenses payable by CytRx.

CytRx intends to use the net proceeds of the offering to fund its clinical
trials of its drug candidate aldoxorubicin and for general corporate purposes,
which may include working capital, capital expenditures and research and
development and other commercial expenditures. CytRx has granted the
underwriters a 30-day option to purchase up to an aggregate of 1.5 million
additional shares of common stock to cover over-allotments, if any. The
offering is expected to close on or about October 14, 2013, subject to
satisfaction of customary closing conditions.

Aegis Capital Corp. is acting as the sole book-running manager for the
offering.

H.C. Wainwright & Co., LLC is acting as a co-lead manager for the offering.

CytRx is offering the shares described above pursuant to a shelf registration
statement on Form S-3, including a base prospectus, that was previously filed
with the Securities and Exchange Commission (SEC) and that is effective. The
securities may be offered only by means of a prospectus. A preliminary
prospectus supplement related to the offering has been filed with the SEC on
October 8, 2013 and a final prospectus supplement related to the offering also
will be filed with the SEC. Electronic copies of the preliminary prospectus
supplement and, when available, the final prospectus supplement, as well as
the accompanying prospectus, may be obtained by either contacting the
representative of the underwriters (as set forth below) or by accessing the
SEC’s website at http://www.sec.gov.

Aegis Capital Corp.
Prospectus Department
810 Seventh Avenue, 18th Floor
New York, New York 10019
Telephone: 212-813-1010
E-mail: prospectus@aegiscap.com

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any securities of CytRx Corporation, nor shall there be any
sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale is not permitted.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company
specializing in oncology. CytRx currently is focused on the clinical
development of aldoxorubicin (formerly known as INNO-206), its improved
version of the widely used chemotherapeutic agent doxorubicin. CytRx is
conducting a global Phase 2b clinical trial with aldoxorubicin as a treatment
for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial
primarily in the same indication and a Phase 1b study of aldoxorubicin in
combination with doxorubicin in patients with advanced solid tumors, and has
completed a Phase 1b pharmacokinetics clinical trial in patients with
metastatic solid tumors. CytRx plans to initiate under a special protocol
assessment a potential pivotal Phase 3 global trial with aldoxorubicin as a
therapy for patients with soft tissue sarcomas whose tumors have progressed
following treatment with chemotherapy. CytRx also is initiating Phase 2
clinical trials with aldoxorubicin in patients with late-stage glioblastoma
(brain cancer) and AIDS-related Kaposi’s sarcoma. CytRx plans to expand its
pipeline of oncology candidates based on a linker platform technology that can
be utilized with multiple chemotherapeutic agents and may allow for greater
concentration of drug at tumor sites. CytRx also has rights to two additional
drug candidates, tamibarotene and bafetinib. CytRx completed its evaluation of
bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic
lymphocytic leukemia (B-CLL), and plans to seek a partner for further
development of bafetinib. For more information about CytRx Corporation, visit
www.cytrx.com.

Forward-Looking Statements

This press release contains statements relating to the proposed offering that
are forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended. Such statements involve risks and
uncertainties, such as market risks and the risk that the conditions to the
closing of the offering will not be satisfied. All forward-looking statements
are based upon information available to CytRx on the date the statements are
first published. CytRx undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.

Contact:

CytRx Corporation
David J. Haen
Vice President, Business Development
310-826-5648 x304
dhaen@cytrx.com
or
Legend Securities, Inc.
John M. Columbia
718-233-2677
jcolumbia@legendsecurities.com
 
Press spacebar to pause and continue. Press esc to stop.